Challenges in the diagnosis and management of new-onset diabetes after transplantation

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Current Diabetes Reports

• Publication date

  2005-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/S11892-005-0009-0PMID 15929866
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Calcium antagonists in patients with type 2 diabetes and hypertension.

  2006cited by this paper
• Steroid or calcineurin inhibitor-sparing immunosuppressive protocols.

  2005cited by this paper
• New Onset Diabetes Mellitus in Patients Receiving Calcineurin Inhibitors: A Systematic Review and Meta‐Analysis

  2004cited by this paper
• New-onset diabetes after transplantation.

  2004cited by this paper
• Allograft diabetic nephropathy may progress to end‐stage renal disease

  2004cited by this paper
• Inhibition of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus in primary, mature islets of transgenic mice.

  2003cited by this paper
• Posttransplant diabetes is a cardiovascular risk factor in renal transplant patients.

  2003cited by this paper
• Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease.

  2003cited by this paper
• Diabetes Mellitus after Kidney Transplantation in the United States

  2003influential reference
• Post-transplant hyperglycaemia: a study of risk factors.

  2003cited by this paper
• New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003.

  2003cited by this paper
• Posttransplantation diabetes: a systematic review of the literature.

  2002cited by this paper
• Neoral® rescue therapy in transplant patients with intolerance to tacrolimus

  2002cited by this paper
• Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus.

  2002cited by this paper
• Post-transplant diabetes: incidence, relationship to choice of immunosuppressive drugs, and treatment protocol.

  2001cited by this paper
• beta-Cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus.

  2001cited by this paper
• Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study.

  2001cited by this paper
• Assignment1 of the human PHLDA1 gene to chromosome 12q15 by radiation hybrid mapping

  2000cited by this paper
• A meta-analysis of immunosuppression withdrawal trials in renal transplantation.

  2000cited by this paper
• Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients.

  2000cited by this paper
• Long-term survival in renal transplant recipients with graft function.

  2000cited by this paper
• Improved graft survival after renal transplantation in the United States, 1988 to 1996.

  2000cited by this paper
• Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation.

  2000cited by this paper
• Glucocorticoids and insulin resistance: old hormones, new targets.

  1999cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Reversal of lesions of diabetic nephropathy after pancreas transplantation.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Diabetes mellitus after renal transplantation.

  1998cited by this paper
• Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes?

  1998cited by this paper
• Mechanism of the Diabetogenic Action of Cyclosporin A

  1998cited by this paper
• Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age.

  1997cited by this paper
• Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study.

  1997cited by this paper
• Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients

  1997cited by this paper
• Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells.

  1996cited by this paper
• Diabetes mellitus after renal transplantation: characteristics, outcome, and risk factors.

  1996cited by this paper
• TRANSCRIPTIONAL INHIBITION OF INSULIN BY FK506 AND POSSIBLE INVOLVEMENT OF FK506 BINDING PROTEIN‐12 IN PANCREATIC β-CELL

  1995cited by this paper
• Steroid‐related complications in the cyclosporine era

  1994cited by this paper
• Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients.

  1994cited by this paper
• Posttransplant diabetes mellitus--a review.

  1994cited by this paper
• Development of an index to predict posttransplant diabetes mellitus

  1993cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• The diabetogenic effects of glucocorticoids are more pronounced in low- than in high-insulin responders.

  1992cited by this paper
• Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients.

  1991cited by this paper
• Diabetes mellitus after renal transplantation in the cyclosporine era--an analysis of risk factors.

  1991cited by this paper
• Post-transplant diabetes mellitus in renal allograft recipients: a matched-pair control study.

  1990cited by this paper
• Direct effects of cyclosporin A on human pancreatic beta-cells.

  1986cited by this paper
• Direct Effects of Cyclosporin A on Human Pancreatic β-cells

  1986cited by this paper
• Posttransplant diabetes in kidney transplant recipients.

  1985cited by this paper
• Diabetes and Cardiovascular Risk Factors: The Framingham Study

  1979influential reference

• Post-Transplant Diabetes: Prevalence, Risk, and Management Challenges

  2022cites this paper
• Drug-induced metabolic alterations in adipose tissue - with an emphasis in epicardial adipose tissue

  2022cites this paper
• Post-transplant diabetes mellitus: incidence, predicting factors and outcomes

  2020cites this paper
• New-Onset Diabetes After Transplantation: Comparison Between a Cyclosporine-Based and a Tacrolimus-Based Immunosuppressive Regimen.

  2018cites this paper
• Glucometabolic disease in the kidney transplant patient.

  2016cites this paper
• THE RATIONALE FOR USE OF INCRETINS IN THE MANAGEMENT OF NEW ONSET DIABETES AFTER TRANSPLANTATION (NODAT).

  2015cites this paper
• Characterization of Remitting and Relapsing Hyperglycemia in Post-Renal-Transplant Recipients

  2015cites this paper
• The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients.

  2010cites this paper
• Nutritional and metabolic issues in solid organ transplantation: targets for future research.

  2009cites this paper
• Posttransplant diabetes and hypertension: Pathophysiologic insights and therapeutic rationale

  2008cites this paper
• Diabetes, the kidney and vascular disease: a complex relationship

  2006cites this paper
• Long-term patient survival: strategies to improve overall health.

  2006cites this paper